These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 22494466)

  • 81. [The current therapies for parkinson's disease. Part I: pharmacological treatment].
    Krygowska-Wajs A; Wszolek ZK; Uitti RJ; Słowinski J; Szczudlik A
    Neurol Neurochir Pol; 2003; 37(3):665-76. PubMed ID: 14593760
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Emerging treatments in Parkinson's disease.
    Albanese A
    Eur Neurol; 1997; 38(3):175-83. PubMed ID: 9363829
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The efficacy of oral adenosine A(2A) antagonist istradefylline for the treatment of moderate to severe Parkinson's disease.
    Vorovenci RJ; Antonini A
    Expert Rev Neurother; 2015; 15(12):1383-90. PubMed ID: 26630457
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease.
    Jiang C; Wan X; Jankovic J; Christian ST; Pristupa ZB; Niznik HB; Sundsmo JS; Le W
    Clin Neuropharmacol; 2004; 27(2):63-73. PubMed ID: 15252266
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.
    Annus Á; Vécsei L
    Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The comparative effects of medical therapies for Parkinson's disease.
    Horn S; Stern MB
    Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585
    [No Abstract]   [Full Text] [Related]  

  • 88. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
    Politi C; Ciccacci C; Novelli G; Borgiani P
    Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [A prospect of treatment for Parkinson's disease in the 21st century].
    Yanagisawa N
    Nihon Rinsho; 2000 Oct; 58(10):1968-74. PubMed ID: 11068433
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
    Sy MAC; Fernandez HH
    Neurotherapeutics; 2020 Oct; 17(4):1331-1338. PubMed ID: 32935299
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach.
    Lees A; Tolosa E; Stocchi F; Ferreira JJ; Rascol O; Antonini A; Poewe W
    Expert Rev Neurother; 2023 Jan; 23(1):15-24. PubMed ID: 36729395
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Opicapone for the treatment of Parkinson's disease.
    Rodrigues FB; Ferreira JJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.
    Reese JP; Dams J; Winter Y; Balzer-Geldsetzer M; Oertel WH; Dodel R
    Expert Opin Pharmacother; 2012 May; 13(7):939-58. PubMed ID: 22475391
    [TBL] [Abstract][Full Text] [Related]  

  • 95. New non-oral drug delivery systems for Parkinson's disease treatment.
    Md S; Haque S; Sahni JK; Baboota S; Ali J
    Expert Opin Drug Deliv; 2011 Mar; 8(3):359-74. PubMed ID: 21314492
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Parkinson's disease management. Part II- discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues.
    Reis J; Encarnação I; Gaspar A; Morales A; Milhazes N; Borges F
    Curr Top Med Chem; 2012; 12(20):2116-30. PubMed ID: 23231391
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
    Vuletić V; Rački V; Papić E; Peterlin B
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281267
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Are All Dopamine Agonists Essentially the Same?
    Torti M; Bravi D; Vacca L; Stocchi F
    Drugs; 2019 May; 79(7):693-703. PubMed ID: 30968290
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Dopamine agonists--pharmacological similarities and differences].
    Honczarenko K; Białecka M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S1-5. PubMed ID: 17941451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.